"Somos FCV un Ecosistema en Salud de referencia nacional e internacional en la prestación de servicios médicos con altos estándares de calidad e innovación. Contamos con hospitales en la categoría nivel cuatro de complejidad y somos la primera institución en el país acreditada por la Joint Commission International - JCI, con el estándar de oro en la atención médica global, gracias a la vocación en la excelencia, investigación y compromiso de nuestro equipo humano, por la salud y bienestar de nuestros pacientes, colaboradores y la comunidad en general. Somos un Ecosistema en Salud referente en el ámbito nacional e internacional en la prestación de servicios médicos con altos estándares de calidad e innovación."

During the past decade, Fundacion Cardiovascular de Colombia conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 17 clinical trials were completed, i.e. on average, 85% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 9 clinical trials were completed. i.e. 90% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fundacion Cardiovascular de Colombia" #1 sponsor was "Fundación Cardiovascular de Colombia" with 8 trials, followed by "Boehringer Ingelheim" with 5 trials sponsored, "Pfizer" with 4 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored and "Pfizer's Upjohn has merged with Mylan to form Viatris Inc." with 3 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fundacion Cardiovascular de Colombia" #1 collaborator was "Novartis" with 2 trials as a collaborator, "The University of Akron" with 2 trials as a collaborator, "Universidad Industrial de Santander" with 2 trials as a collaborator, "Universidad de Santander" with 2 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "Fundacion Cardiovascular de Colombia" are "Atrial Fibrillation" (3 trials), "Cardiovascular Disease" (2 trials), "Migraine" (2 trials), "Stroke" (2 trials) and "Aortic Valve Stenosis" (1 trials). Many other conditions were trialed in "Fundacion Cardiovascular de Colombia" in a lesser frequency.

Most popular intervention types in "Fundacion Cardiovascular de Colombia" are "Drug" (24 trials), "Other" (6 trials), "Biological" (4 trials), "Device" (3 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Erenumab Dose 1" (2 trials), "Erenumab Dose 2" (2 trials), "Erenumab Dose 3" (2 trials) and "Nipocalimab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Fundacion Cardiovascular de Colombia" are 34 trials for "All" genders.

Currently, there are NaN active trials in "Fundacion Cardiovascular de Colombia". undefined are not yet recruiting, 7 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Fundacion Cardiovascular de Colombia, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Fundacion Cardiovascular de Colombia, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 2 trials that are defined as “Not Applicable".

Fundacion Cardiovascular de Colombia has several departments that took part in Clinical trials: "Fundación Cardiovascular de Colombia" - 2 trials